Page results
-
Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.
-
More people with dementia in the UK will be able to take part in research and help accelerate the development of new treatments, as the Government announces £49.9 million of new funding to build a network of dementia trials sites across the country.
-
Your acute myeloid leukaemia (AML) treatment will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Acute lymphoblastic leukaemia (ALL) is a form of cancer that affects the cells in the bone marrow, the soft material inside your bones.
-
UCLH has treated the first brain cancer patient with immunotherapy prior to standard treatment as part of a pioneering trial.
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Tens of thousands of people in England who have hepatitis C could now get tested and treated thanks to a new mobile health unit arriving to coincide with World Hepatitis Day on 28 July.
-
Information about the new government support available to help people pay their energy bills.
-
The haematology and critical care services in our flagship University College Hospital Grafton Way Building are now open.
-
UCLH is making the change from single use to named reusable fabric theatre hats for staff working in operating theatres.
File results
-
FOI/2024/0076 - Patient Portal contract and supplier
-
FOI/2024/0078 - Locally employed doctors at Trust
-
FOI/2024/0079 - Water procurement
-
FOI/2024/0080 - Patient treatment for botched non-surgical procedures
-
FOI/2024/0094 - Record Freedom of Information data 2023
-
FOI/2024/0095 - Hospital at home - Discharge and discharge to assess pathways
-
FOI/2024/0096 - Waiting lists for gynaecology treatment 2021-2024
-
FOI/2024/0097 - Laboratory Information Management System (LIMS)/ pathology IT system
-
FOI/2024/0101 - Immunoglobulin drug treatments
-
FOI/2024/0108 - Clinical letters/ EPR, PAS, patient portal systems, hybrid mail contract